Seeking Alpha

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM ...
Nasdaq

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to ...
Nasdaq

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

-- Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo1 -- CAMBRIDGE, Mass., Dec.
ksn.com

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug ...
FOX31 Denver

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental ...